NEW YORK – Israeli diagnostics firm Ibex Medical Analytics said on Tuesday that the UK National Health Service has decided to make its AI-enabled breast and prostate cancer tests available to 25 NHS trusts.
According to the Tel Aviv-based company, it has received multiple contracts for its products through PathLAKE, a center of excellence consortium backed by Innovate UK, the government's national innovation agency. Further financial details were not disclosed.
PathLAKE — the Pathology Image Data Lake for Analytics Knowledge and Education — was established in 2019 to deliver artificial intelligence-powered digital pathology tools to NHS trusts and UK universities. Partners include Nottingham University Hospitals, University Hospitals Coventry & Warwickshire, Oxford University Hospitals, and Cambridge University Hospitals. PathLAKE is based in Coventry, in central England.
With the new contracts secured through PathLAKE, 25 NHS trusts will now be able to obtain Ibex's Galen Breast and Galen Prostate tests. Ibex's Galen platform can be used by pathologists to detect and grade different cancers. Its algorithms can analyze images from biopsies automatically, delivering information that informs case prioritization work lists, cancer heat maps, tumor grading and measurement, and reports.
Ibex announced last month that it had obtained a CE-IVDR certificate under the new European In Vitro Diagnostic Regulation for its Galen Prostate product. It said at the time that it aims to gain a CE-IVDR certificate for its Galen Breast product this year. Its solutions previously held CE-IVD certificates compliant with the In Vitro Diagnostics Directive, which the IVDR replaced when it began to apply in May 2022.
The products have also been registered with the UK Medicines and Healthcare Products Regulatory Agency, which regulates medical products in the UK.
Richard Nicholson, director of UK sales at Ibex, said in a statement that the company plans to support the adoption of its products in other regions within the UK. "Building upon our successful AI deployments in NHS Wales, and our existing projects with hospitals and labs in England, we are uniquely positioned to further strengthen the adoption, deployment, and routine use of AI in pathology across the UK," Nicholson said.